The predictive role of protease-activated receptor (PAR-1) polymorphisms and activated platelet microparticles in the severity of atherosclerosis – preliminary studies

<p><span style="color:rgb( 44 , 54 , 58 );font-family:monospace;font-size:13px;font-style:normal;font-weight:400;letter-spacing:normal;text-align:left;text-indent:0px;text-transform:none;word-spacing:0px;white-space:normal;background-color:rgb( 255 , 255 , 255 );display:!important;float:none">The study analyzes the role of the PAR-1 receptor, present on platelets and platelet microparticles (PMPs), in diabetic macroangiopathy (DM) and obliterative atherosclerosis (AO). The applied molecular, laboratory, and statistical methods made it possible to assess PAR-1 activation, its polymorphisms, platelet/PMP (PLT/PMP) activity, and hemostatic factors. In DM, the −506D/D and IVS-14A/A polymorphisms occurred more frequently, whereas −506I/D predominated in AO, suggesting a protective role of the I allele. Increased PMP activity in DM indicates their involvement in the progression of atherosclerosis, while reduced PAR-1 activation in AO may be associated with lower levels of von Willebrand factor. With a high percentage of PMPs, PAR-1 activation increased the risk of AO. Quantitative assessment of PAR-1 and PMPs may be useful for predicting the severity of atherosclerosis.</span></p>